# Trilostane for Androgen-Independent Prostate Cancer

> **NCT00181597** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 24 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Trilostane
- **DRUG:** Hydrocortisone

## Key facts

- **NCT ID:** NCT00181597
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00181597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00181597, "Trilostane for Androgen-Independent Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00181597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*